BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Get Free Report) has received a consensus rating of "Moderate Buy" from the twenty-five brokerages that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, six have issued a hold rating, fifteen have assigned a buy rating and three have issued a strong buy rating on the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $87.22.
BMRN has been the topic of a number of recent analyst reports. Stifel Nicolaus lowered their price target on BioMarin Pharmaceutical from $70.00 to $66.00 and set a "hold" rating on the stock in a research report on Tuesday, November 3rd. UBS Group assumed coverage on BioMarin Pharmaceutical in a research report on Thursday, October 15th. They issued a "buy" rating and a $88.00 price objective for the company. Canaccord Genuity Group raised their price objective on BioMarin Pharmaceutical from $111.00 to $114.00 and gave the company a "buy" rating in a research report on Monday, August 10th. Wall Street Zen upgraded BioMarin Pharmaceutical from a "hold" rating to a "buy" rating in a research note on Sunday, November 8th. Finally, Royal Bank Of Canada decreased their target price on BioMarin Pharmaceutical from $62.00 to $60.00 and set a "sector perform" rating on the stock in a report on Tuesday, November 3rd.
Get Our Latest Stock Report on BMRN
Insiders Place Their Bets
In other BioMarin Pharmaceutical news, EVP Gregory Friberg sold 5,147 shares of the firm's stock in a transaction on Wednesday, November 18th. The stock was sold at an average price of $58.81, for a total transaction of $302,695.07. Following the completion of the sale, the executive vice president owned 42,585 shares of the company's stock, valued at $2,504,423.85. This trade represents a 10.78% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 0.68% of the company's stock.
Hedge Funds Weigh In On BioMarin Pharmaceutical
Several large investors have recently modified their holdings of BMRN. Parkside Financial Bank & Trust boosted its holdings in BioMarin Pharmaceutical by 70.3% in the 2nd quarter. Parkside Financial Bank & Trust now owns 453 shares of the biotechnology company's stock valued at $26,000 after purchasing an additional 187 shares during the period. Oregon Public Employees Retirement Fund grew its position in shares of BioMarin Pharmaceutical by 0.5% during the 3rd quarter. Oregon Public Employees Retirement Fund now owns 40,117 shares of the biotechnology company's stock worth $2,407,000 after purchasing an additional 200 shares in the last quarter. North Dakota State Investment Board grew its position in shares of BioMarin Pharmaceutical by 3.9% during the 3rd quarter. North Dakota State Investment Board now owns 5,872 shares of the biotechnology company's stock worth $352,000 after purchasing an additional 218 shares in the last quarter. Signaturefd LLC increased its holdings in shares of BioMarin Pharmaceutical by 16.7% during the third quarter. Signaturefd LLC now owns 2,316 shares of the biotechnology company's stock worth $139,000 after purchasing an additional 331 shares during the period. Finally, Bessemer Group Inc. increased its holdings in shares of BioMarin Pharmaceutical by 0.5% during the third quarter. Bessemer Group Inc. now owns 90,036 shares of the biotechnology company's stock worth $5,401,000 after purchasing an additional 447 shares during the period. 98.71% of the stock is owned by institutional investors.
BioMarin Pharmaceutical Stock Down 0.0%
BioMarin Pharmaceutical stock opened at $61.42 on Friday. The firm has a market capitalization of $11.90 billion, a PE ratio of -614.20, a P/E/G ratio of 0.82 and a beta of 0.21. The company's 50-day moving average is $58.42 and its 200-day moving average is $58.54. BioMarin Pharmaceutical has a fifty-two week low of $49.26 and a fifty-two week high of $70.98. The company has a debt-to-equity ratio of 0.56, a current ratio of 2.44 and a quick ratio of 1.32.
BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last issued its earnings results on Monday, November 2nd. The biotechnology company reported $0.23 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.05) by $0.28. BioMarin Pharmaceutical had a negative net margin of 0.52% and a positive return on equity of 5.58%. The company had revenue of $1.02 billion for the quarter, compared to analysts' expectations of $1.02 billion. During the same period in the prior year, the firm earned $0.12 EPS. BioMarin Pharmaceutical's quarterly revenue was up 32.0% compared to the same quarter last year. Sell-side analysts anticipate that BioMarin Pharmaceutical will post 2.20 earnings per share for the current year.
BioMarin Pharmaceutical Company Profile
(
Get Free Report)
BioMarin Pharmaceutical is a biotechnology company focused on developing and commercializing medicines for people with rare genetic diseases. Its work includes research, clinical development, manufacturing and distribution of therapies for conditions that often have limited treatment options. The company's marketed treatments address disorders including phenylketonuria, mucopolysaccharidosis, late-infantile neuronal ceroid lipofuscinosis, achondroplasia and hemophilia A. Its products include Kuvan and Palynziq for phenylketonuria, Vimizim for Morquio A syndrome, Brineura for CLN2 disease, Voxzogo for achondroplasia and Roctavian for hemophilia A. Founded in 1997 and headquartered in San Rafael, California, BioMarin serves patients and healthcare providers in the United States and international markets, including Europe.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider BioMarin Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioMarin Pharmaceutical wasn't on the list.
While BioMarin Pharmaceutical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.